The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
- Approximately 30% of Doctors Conduct ALK Gene Test in All Patients: Pfizer Survey
November 28, 2012
- Pfizer Launches Glycylcycline Antibiotic Tygacil
November 27, 2012
- 8 Companies’ Entries to COPD Market Turn It into Red Ocean
November 27, 2012
- Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
- Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
- Teva Pharma to Temporarily Discontinue Marketing of Risperidone Generics Due to Halt in Bulk Drug Production
November 26, 2012
- Fuji Pharma, Mochida Receive Approvals for Biosimilar Gran
November 26, 2012
- Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
- Joint Venture with Actavis to Continue Operations: ASKA Pres. Yamaguchi
November 22, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…